To promote the widespread use of iPS cell–derived somatic cells in drug development, academics and iPS cell companies say they need to prove that the derived cells faithfully capture relevant disease phenotypes and biological processes, and that the cells can be produced in the quantity, consistency and purity needed to meet pharma’s standards.